Scientific Programme

The below represents the latest HIV Glasgow programme, now featuring abstracts accepted for oral presentation within the main programme and those accepted for poster discussions over the lunchtimes of Monday and Wednesday. The programme promises to be an exciting one with much audience interaction and input.

The Congress has been accredited by the EACCME to provide CME activity for medical specialists. A total of 19 credits has been awarded. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS), Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Delegates wishing to claim credits will be scanned into and out of the auditoria during the Congress and the information will be held on file and made available to the awarding CME body if requested.

Sunday 28 October
Monday 29 October
Tuesday 30 October
Wednesday 31 October

Sunday 28 October

12:00–13:30Interactive Case Study Session
In collaboration with the University of Liverpool Drug Interactions website:

12.00–12.15HIV pharmacology in 2018
Saye Khoo, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool,

12.15–12.40Case 1: TB co-infection
Marta Boffito, HIV and Sexual Health – Kobler Clinic, Chelsea Westminster
Hospital, London, UK

12.40–13.05Case 2: HIV-HCV and PWIDS
Erica Peters, Brownlee Centre for Infectious Diseases, NHS Greater Glasgow
Clyde, Glasgow, UK

13.05–13.30Case 3: Pregnancy
Presenter:Mas Chaponda, Royal Liverpool and Broadgreen University Hospitals NHS
Trust, Liverpool, UK

Discussants: Fiona Marra, Advanced Pharmacist HIV/HCV, Gartnavel Hospital,
Glasgow, UK
Mohammed Lamorde, Infectious Diseases Institute, Makerere University,
Kampala, Uganda

Jonathan Schapiro, National Haemophilia Center, Sheba
Medical Center, Tel Aviv, Israel


14:30–16:00Industry Symposium


16:30–16:40Official Opening
Andrew Phillips, University College London, London, UK

Welcome from Glasgow City
Representative from Glasgow City Council, Glasgow, UK

16:40–18:35Opening Scientific Session
Co-Chairs:Praphan Phanuphak, Thai Red Cross Research Centre, Bangkok, Thailand
Andrew Phillips

16:40–16:55Celebrating a Champion of the Response to HIV
Remembering David Cooper
Tribute by: Sean Emery, University of New South Wales, Sydney, Australia

16:55–17:35Joep Lange and Jacqueline van Tongeren Memorial Lecture: HIV/AIDS, global
health and the Sustainable Development Goals

Kevin M De Cock, CDC Country Office, Nairobi, Kenya
Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of
their commitment and passion to rid the world of HIV/AIDS

Introduction by: Praphan Phanuphak

17:35-18:05Strategies to reduce HIV incidence in Europe
Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC),
Stockholm, Sweden

18:05-18:35PrEP: what’s happening in Europe and the World in general
Sheena McCormack, MRC Clinical Trials Unit at UCL, London, UK

18:35–19:30Welcome Reception

Back to the top of the page

Monday 29 October

08:30–10:10Living Well with HIV: Ongoing Challenges
Co-Chairs:Peter Reiss, Department of Global Health, Amsterdam UMC,
University of Amsterdam, Amsterdam, The Netherlands
Caroline Sabin, Institute for Global Health, University College London,
London, UK

08:30–08:50Retention and re-engagement in care: a combination approach again required
Fiona Burns, Centre for Sexual Heath and HIV Research,
and Royal Free Hospital, London, UK

08:50–09:10HIV and ageing: challenges and goals
Julian Falutz, Department of Medicine, McGill University, Montreal, Canada

09:10–09:2548-week changes in biomarkers in subjects with high cardiovascular risk
switching from ritonavir-boosted protease inhibitors to dolutegravir:

the NEAT022 study
Esteban Martinez, Infectious Disease, Hospital Clínic & University of Barcelona,
Barcelona, Spain

09:25-09:40Risk of hospitalisation according to gender, sexuality and ethnicity among
people with HIV in the modern ART era

Sophia Rein, Institute for Global Health, University College London, London, UK

09:40-09:55Multimorbidity and risk of death differs by gender in people living with HIV in
the Netherlands: the ATHENA cohort study

Ferdinand Wit, Stichting HIV Monitoring, Amsterdam University Medical Centers,
location Academic Medical Center, Amsterdam, The Netherlands

09:55-10:10The economic burden of comorbidities among people living with HIV in Germany: a
cohort analysis using health insurance claims data

Eva Wolf, MUC Research, Munich, Germany



11:00-11:10In Memory of Mark Wainberg
Mark made an enormous contribution to both the basic science and global
politics of the HIV epidemic. He was a president of the International AIDS
Society, received Canada’s highest civilian award and was an extremely active
member of the scientific committee of HIV Glasgow for over 20 years.
Tribute by: Ian Weller, University College London, London, UK

11:10–11:55Lock Lecture
HIV Glasgow is honoured to have been chosen by the Royal College of Physicians
and Surgeons of Glasgow to present the Lock Lecture as part of the Scientific

11:10-11:15Lock Lecture: introduction
David Galloway, President, Royal College of Physicians and Surgeons of Glasgow,
Glasgow, UK

11:15-11:55STIs among MSM: new challenges in prevention, diagnosis and treatment
Jean-Michel Molina, Department of Infectious Diseases and University of Paris 7,
St Louis Hospital, Paris, France

11:55-13:30Scientific Posters and Lunch

12:25-13:15Comorbidities: Lunchtime Poster Discussion Session
Co-Chairs:Georg Behrens, Department for Clinical Immunology and
Rheumatology, Hannover Medical School, Hannover, Germany
Sarah Pett, UCL Institute of Clinical Trials and Methodology, London, UK

12:25-12:35Incidence and risk factors associated with osteoporosis-related fractures (ORF)
among PLWHIV in British Columbia (BC), Canada
José Barletta, Infectious Diseases Division, Hospital Juan A. Fernández, Buenos
Aires, Argentina

12:35-12:45Phase IIIb, randomized, open-label study to evaluate switching from a
tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/
emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1
infected participants aged ≥60
Franco Maggiolo, USC Malattie Infettive, Azienda Ospedaliera Papa Giovanni
XXIII, Bergamo Italy

12:45-12:55Haematological manifestations in virologically-suppressed people living with HIV
Delal Akdag, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

12:55-13:05Increases in lipid profile after switch from TDF to TAF-based HAART regimens in
a cohort of HIV-positive patients: is it clinically relevant?
Lidia Gazzola, Infectious Disease, ASST Santi Paolo e Carlo, Milan, Italy

13:05-13:15Factors associated with HIV-associated neurocognitive disorder in an
unselected cohort in East and South London: the HAND study
Simon Rackstraw, HIV, Barts Health NHS Trust, London, UK

12:25-13:15Substances, Drugs and Outcomes: Lunchtime Poster Discussion Session
Co-Chairs:Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of
Cape Town, Cape Town, South Africa, and Immediate Past-President, IAS
Simon Collins, HIV i-Base, London, UK

12:25-12:35Risky Alcohol Consumption and Associated Health Behaviour among HIV-
positive and HIV-negative Patients in a UK Sexual Health and HIV Clinic: the
Emmi Suonpera, Institute for Global Health, University College London, London, UK

12:35-12:45Chemsex drugs on the rise among MSM: a longitudinal analysis of the Swiss
HIV Cohort Study from 2007 to 2017
Benjamin Hampel, Infectious Diseases and Hospital Epidemiology, University
Hospital Zurich, Zurich, Switzerland

12:45-12:55Polypharmacy and drug-drug interactions in HIV-infected subjects in the region
of Madrid (Spain): a population-based study
Juan Berenguer, Instituto de Investigacion Sanitaria, Hospital General
Universitario Gregorio Marañón, Madrid, Spain

12:55-13:05Using mechanistic physiologically-based pharmacokinetic models to assess
prenatal drug exposure: thalidomide versus efavirenz as case studies
Shakir Atoyebi, Department of Pharmaceutical Chemistry, Obafemi Awolowo
University, Ile Ife, Nigeria

13:05-13:15Cumulative safety review of elvitegravir and bictegravir use during pregnancy
and risk of neural tube defects
Terry Farrow, Pharmacovigilance & Epidemiology, Gilead Sciences, Foster City,

13:30-15:15Drug Interactions, ARV Toxicity and Switching
Co-Chairs:Anastasia Antoniadou, Division of Internal Medicine IV, National and
Kapodistrian, University of Athens, Athens, Greece

David Back, Molecular and Clinical Pharmacology,
University of Liverpool, UK

13:30–13:50The top 10 DDIs in day to day clinical management of HIV
Catia Marzolini, Division of Infectious Diseases & Hospital Epidemiology,
University Hospital Basel, Basel, Switzerland

13:50-14:10Adverse effects of current ARVs: myths and realities
Patrick Mallon, Mater Misericordiae University Hospital, Dublin

14:10-14:25Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in
12 randomised trials of PrEP (n=15,678)

Victoria Pilkington, Faculty of Medicine, Imperial College London, London, UK

14:25-14:40Dual therapy with PI/r+3TC or PI/r+TDF shows non-inferior HIV RNA
suppression and lower rates of discontinuation for adverse events, versus
triple therapy. Meta-analysis of seven randomised trials in 1624 patients

Zara Liew, Faculty of Medicine, Imperial College London, London, UK

14:40-14:55No significant changes to residual viremia after switch to dolutegravir and
lamivudine in a randomized trial

Babafemi Taiwo, Division of Infectious Diseases, Northwestern University,
Chicago, IL, USA


15:15–17:00Challenging Cases in HIV
In collaboration with the International Antiviral Society-USA (IAS-USA)
Moderators:Carlos del Rio, Rollins School of Public Health,
Atlanta, GA, USA
Ian Williams, Institute for Global Health, University College London,
London, UK

15:15–15:25Welcome and introduction
Carlos del Rio

15:25-15:55Case 1: PrEP
Roy M Gulick, Weill Cornell Medicine, New York, NY, USA

15:55–16:25Case 2: ART: initiating treatment
Chloe Orkin, Ambrose King Centre, Royal London Hospital, London, UK

16:25–16:55Case 3: ART: treatment failure?
Manuel Battegay, Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Basel, Basel, Switzerland

Panel:Manuel Battegay
Carlos del Rio
Roy M Gulick
Chloe Orkin
Ian Williams


17:30–19:00Industry Symposium

Back to the top of the page

Tuesday 30 October

08:30–10:00Industry Symposium


10:30–12:30Approaches to Treatment and Cure
Co-Chairs:Giulia Marchetti, Dept of Health Sciences, Clinic of
Infectious Diseases, University of Milan, Milan, Italy
Jonathan Schapiro

10:30-10:45Phase III randomized, controlled clinical trial of bictegravir coformulated with
FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF
in treatment-naïve HIV-1 positive adults: Week 96
Hans-Jürgen Stellbrink, ICH Study Center, Hamburg, Germany

10:45-11:00Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/
tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in
antiretroviral treatment (ART)-naïve, HIV-1-infected adults: AMBER
Week 96 results

Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London, London, UK

11:00-11:15Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-
based triple therapy

Babafemi Taiwo, Division of Infectious Diseases, Northwestern University,
Chicago, IL, USA

11:15-11:30The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/
dolutegravir regimens prescribed in treatment-experienced patients

Flaminia Olearo, Infectious Diseases, University Hospital of Geneva, Geneva,

11:30–11:50Approaches towards a cure for HIV
Sarah Fidler, Department of GUM and HIV Medicine, Imperial College and
Imperial College NHS Trust, London UK

11:50–12:10HIV cure and cancer immunotherapy: cross-disciplinary research at its best
Steven G Deeks, Department of Medicine, University of California,
San Francisco, CA, USA 


12:30–14:00Scientific Posters and Lunch

12:45-13:45Quality of Life Across Different Age Groups of People Living
with HIV: A Community Perspective

In collaboration with the European AIDS Treatment Group (EATG)
Co-Chairs:Lene Ryom, Centre of Excellence for Health, Immunity and
Infections, Copenhagen, Denmark
Alain-Volny Anne, Paris, France

12:45-12:50Introduction and Project Overview
Koen Block, EATG, Brussels, Belgium

12:50-13:00People living with HIV/AIDS aged 50+
Brian West, EATG, Edinburgh, UK

13:00-13:10Children and adolescents (aged 0-25)
Sanja Belak Skugor, University Hospital for Infectious Disease, Zagreb, Croatia
Caroline Foster, Imperial College NHS Trust, London, UK

13:10-13:20People who have lived with HIV/AIDS at least 10 years (aged 18-50)
Jackie Morton, EATG, UK

13:20-13:50Panel Discussion:Mario Cascio, EATG, Palermo, Italy
Nikos Dedes, EATG

14:00–15:30#Adolescent Lives Matter
In collaboration with the International AIDS Society (IAS)
Moderators:Yana Panfilova, Student, Academy of Labour, Social Work and
Tourism, Kiev, Ukraine, and HIV activist and founder of Teenergizer,
a youth movement
Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape
Town, Cape Town, South Africa, and Immediate Past-President, IAS

14:00-14:15Living with it: complications of long term HIV
Rashida Ferrand, London School of Hygiene and Tropical Medicine, London, UK, and
Harare, Zimbabwe 

14:15-14:30Taking it: PrEP experiences among adolescent MSM
Sybil Hosek, John Stroger Hospital of Cook Country, Chicago, IL, USA

14:30-14:45Staying with it: novel ways to increase adolescent adherence
Caroline Foster, Imperial College NHS Trust, London, UK

14:45-15:00Dealing with it: mental health and stigma: report from a cohort of YPLHIV
in the Ukraine

Heather Bailey, Population, Policy and Practice Programme, UCL Great Ormond Street
Institute of Child Health, London, UK 

15:00-15:15Adolescent friendly – really?
Mercy Ngulube, Chair, Children’s HIV Association’s Youth Committee, UK


15:30–17:00Mental Health and HIV: what we all need to know
In collaboration with the British HIV Association (BHIVA)
Co-Chair:Tamás Bereczky, European AIDS Treatment Group, Budapest, Hungary
Chloe Orkin, Ambrose King Centre, Royal London Hospital,
London, UK; and Chair, BHIVA

15:30–15:40BHIVA Mental Health Audit
Chloe Orkin

15:40–15:55Prevalence of mental health problems among people living with HIV 
Fiona Lampe, Infection & Population Health, University College London, London, UK

15:55–16:10Discrimination in EU healthcare: the community perspective 
Caroline Izambert, AIDES, Paris, France

16:10–16:25Important DDIs: to include QT/PR interval concerns
Laura Waters, Mortimer Market Centre, University College London Hospitals,
London, UK

16:25–17:00Q & A 


17:30–19:00Industry Symposium

19:00–19:45Poster reception

Back to the top of the page

Wednesday 31 October

08:30–08:50HIV and Migration: a renewed challenge
Co-Chair:Karine Lacombe, Infectious and Tropical Diseases Department,
Saint-Antoine Hospital (AP-HP), Paris, France
Stefan Mauss, Center for HIV and Hepatogastroenterology, Düsseldorf,


08:30–08:50HIV and migration: a renewed challenge
Julia Del Amo, National Center for Epidemiology, Institute of Health Carlos III,
Madrid, Spain

08:50-10:00 Co-infections: TB and Viral Hepatitis

08:50–09:10HIV-associated tuberculosis: diagnosis, management and prevention 
Graeme Meintjes, University of Cape Town, Cape Town, South Africa

09:10-09:30Eliminating hepatitis C: a public health perspective
Margaret Hellard, Burnet Institute, Melbourne, Australia; and Viral Hepatitis Services,
Department of Infectious Diseases, The Alfred Hospital Melbourne, Australia 

09:30–09:45Minimum prices of generic hepatitis C direct acting antivirals fall below US$50
per person cured

Andrew Hill, Translational Medicine, University of Liverpool, Liverpool, UK

09:45–10:00Long-term follow-up of HIV-HBV co-infected patients according to the use of
anti-HBV active drugs

Andrea Calcagno, Unit of Infectious Diseases, Department of Medical Sciences,
University of Torino, Torino, Italy


10:30–12:00What Women Want
Joint session in collaboration with the European AIDS Clinical Society (EACS) and
Women Against Viruses in Europe (WAVE)

Co-Chairs:Justyna D Kowalska, Hospital for Infectious Diseases, Medical
University of Warsaw, Warsaw, Poland
Fiona Mulcahy, Department of Genito-Urinary Medicine & Infectious
Diseases, St James’ Hospital, Dublin, Ireland

10:30–10:55PrEP for women in Europe: case presentation and lecture
Agnieszka Wroblewska, HIV Out-Patient CLinic, Hospital for Infectious Diseases,
Warsaw, Poland (Case) 

Nneka Nwokolo, Sexual Health and HIV Medicine, Chelsea and Westminster
Hospital, London, UK (Lecture)

10:55-11:20Pharmacokinetic studies in women and its impact on clinical practice: case
presentation and lecture

Eugénie Colin-Benoit, Department of Infectious Diseases, University Hospital Bern,
Bern, Switzerland (Case)

Karoline Aebi-Popp, Department of Infectious Diseases, University Hospital Bern,
Bern, Switzerland (Lecture)

11:20–11:45HCV treatment and pregnancy: case presentation and lecture 
Marta Vasylyev, Out Patient Department, Lviv Regional AIDS Center,
Lviv, Ukraine (Case)

Karine Lacombe, Infectious and Tropical Diseases Department, Saint Antoine
Hospital (AP-HP), Paris, France (Lecture)

11:45–12:00Oral Papers

12:00–13:20Scientific Posters and Lunch

12:15-13:05ART: Lunchtime Poster Discussion Session
Co-Chairs:Nadia Ahmed, Centre of Excellence for Adolescents Health and
Wellbeing, Desmond Tutu HIV Foundation and Faculty of Health
Sciences, University of Cape Town, Cape Town, South Africa
Ian Williams

12:15-12:25High prevalence of previously undocumented baseline M184V/I does not
affect virologic outcome in virologically-suppressed patients switching to
bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from a boosted-
protease inhibitor-based regimen

Richard Haubrich, Medical Affairs, Gilead Sciences, Foster City, CA, USA

12:25-12:35Comparison of viral replication below 50c/mL for two drug (DTG+RPV) versus
three drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and
SWORD-2 studies

Mark Underwood, Clinical Virology, ViiV Healthcare, Research Triangle Park, NC, USA

12:35-12:45Safety, efficacy and durability of long-acting CAB and RPV as two-drug IM
maintenance therapy for HIV-1 infection: LATTE-2 Week 160 results

David Margolis, Clinical Development, ViiV Healthcare, Research Triangle Park,

12:45-12:55Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to
dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in
antiretroviral treatment-naïve adults with HIV-1 infection: subgroup analyses
in the GEMINI studies

Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London,
London, UK

12:55-13:05Incidence and determinants of antiretroviral switching away from TDF-based
backbone in the recent years in the Icona Foundation Cohort

Alessandra Vergori, L.Spallanzani, IRCCS HIV/AIDS Unit, National Institute for
Infectious Diseases, Rome, Italy

12:15–13:10An HIV outbreak among people who inject drugs in Glasgow

Co-Chairs:Andrew Leigh Brown, University of Edinburgh, Edinburgh, UK
Emma Thomson, Centre for Virus Research, Institute of Infection,

Immunity & Imflammation, Glasgow, UK

Andrew Leigh Brown

12:25-12:35Using real-time phylodynamic analysis to assess and guide public
health interventions in an HIV outbreak among PWIDs in Scotland

Amanda Bradley-Stewart, Virology, NHS Greater Glasgow and Clyde, Glasgow, UK

12:35-12:40Is early ART achievable in PWIDs living with HIV?
Rebecca Metcalfe, NHS Greater Glasgow and Clyde Brownlee Centre, Gartnavel
General Hospital, Glasgow, UK

12:40-12:45An outbreak of HIV amongst homeless PWIDs: an innovative HIV
clinical service model adaptation leading to successful clinical outcomes

Erica Peters

12:45-12:50Providing HIV ARVs via community pharmacies alongside opiate
replacement therapy (ORT) during an HIV outbreak amongst PWIDs

Regina O’Hara, Brownlee Outpatients, Gartnavel General Hospital, Glasgow, UK
Infectious Diseases, Rome, Italy

12:50-12:55Nurses at the forefront: a new HIV service model for PWIDs in Glasgow
Patricia Anderson, Brownlee Centre, Gartnavel General Hospital, Glasgow, UK

12:55-13:10Panel Discussion

13:20–15:00Late Breakers/Hot Topics
Co-Chairs:Deniz Gökengin, Department of Infectious Diseases and Clinical
Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey
Roy Gulick

13:20–13:45New ARV drugs and strategies
Alexandra Calmy, HIV/AIDS Unit, Geneva University Hospital, Geneva, Switzerland

13:45-14:00Dolutegravir- versus an efavirenz 400mg-based regimen for the initial
treatment of HIV-infected patients in Cameroon: 48-week efficacy results of
the NAMSAL ANRS 12313 trial
Eric Delaporte, TransVIHMI et CHU Montpellier IRD-INSERM, Université
Montpellier, Montpellier, France

14:00-14:15Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical
Jay Grobler, Infectious Disease Biology, Merck Sharp & Dohme, a subsidiary of
Merck & Co., Inc., Kenilworth, NJ, USA

14:15-14:30Week 48 safety and efficacy of the HIV-1 attachment inhibitor prodrug
fostemsavir in heavily treatment-experienced participants (BRIGHTE Study)
Phase 3 Study of fostemsavir in heavily treatment-experienced HIV-1 infected
participants: BRIGHTE Week 48 subgroup analysis in randomized cohort
Peter Ackerman, Clinical Development, ViiV Healthcare, Branford, CT USA

14:30-14:45Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded
Access Program
Zvi Cohen, Medical Affairs, Theratechnologies Inc., Montreal, Canada

14:45-15:00Distribution in cerebrospinal fluid (CSF) of cabotegravir (CAB) and rilpivirine
(RPV) after intramuscular administration of long-acting (LA) injectable
suspensions in HIV-1 infected patients
Scott Letendre, Antiviral Center, University of California, San Diego, CA, USA

15:00–15:10Congress Closing Remarks
Giulio Corbelli, European AIDS Treatment Group (EATG), Brussels, Belgium and
Bologna, Italy

Andrew Phillips

Back to the top of the page